Revive Therapeutics Announces Extension of Proposed Private Placement
Revive Therapeutics (OTCQB: RVVTF) has announced an extension of its private placement offering. The company aims to raise up to $650,000 through the issuance of up to 30,952,381 units at $0.021 per unit. Each unit includes one common share and one warrant exercisable at $0.05 for 36 months.
The company has already completed a first tranche in August 2025, raising $60,900 through 2,900,000 units, leaving $589,000 worth of units available. The proceeds will be used for working capital and trade payables settlement. The securities will have a four-month and one-day hold period from issuance.
Revive Therapeutics (OTCQB: RVVTF) ha annunciato un'estensione della sua offerta in private placement. La società punta a raccogliere fino a $650.000 tramite l'emissione di fino a 30.952.381 unità al prezzo di $0,021 per unità. Ogni unità comprende una azione ordinaria e una warrant esercitabile a $0,05 per 36 mesi.
La prima tranche è già stata completata nell'agosto 2025, raccogliendo $60.900 attraverso 2.900.000 unità, lasciando disponibili unità per un valore residuo di $589.000. I proventi saranno destinati al capitale circolante e al pagamento dei debiti commerciali. Le securities saranno soggette a un periodo di lock-up di quattro mesi e un giorno dalla data di emissione.
Revive Therapeutics (OTCQB: RVVTF) ha anunciado una prórroga de su colocación privada. La compañía pretende recaudar hasta $650,000 mediante la emisión de hasta 30.952.381 unidades a $0.021 por unidad. Cada unidad incluye una acción común y una garantía (warrant) ejercitable a $0.05 durante 36 meses.
La primera tranche ya se completó en agosto de 2025, recaudando $60,900 mediante 2,900,000 unidades, por lo que quedan disponibles unidades por un valor de $589,000. Los fondos se usarán para capital de trabajo y liquidación de cuentas comerciales. Los valores tendrán un período de retención de cuatro meses y un día desde la emisión.
Revive Therapeutics (OTCQB: RVVTF)가 사모 발행(프라이빗 플레이스먼트) 연장을 발표했습니다. 회사는 단가 $0.021으로 최대 30,952,381 단위를 발행해 최대 $650,000를 조달하는 것을 목표로 하고 있습니다. 각 단위에는 보통주 1주와 행사 가격 $0.05의 워런트 1개(만기 36개월)가 포함됩니다.
회사는 이미 2025년 8월 첫 번째 트랜치를 완료해 2,900,000 단위로 $60,900를 조달했으며, 남은 발행 가능 금액은 $589,000입니다. 조달금은 운전자본과 외상매출금(매입채무) 정리에 사용됩니다. 증권은 발행일로부터 4개월과 1일간의 보호예수 기간이 적용됩니다.
Revive Therapeutics (OTCQB: RVVTF) a annoncé une extension de son placement privé. La société vise à lever jusqu'à 650 000 $ en émettant jusqu'à 30 952 381 unités au prix de 0,021 $ par unité. Chaque unité comprend une action ordinaire et un bon de souscription exerçable à 0,05 $ pendant 36 mois.
La première tranche a déjà été réalisée en août 2025, levant 60 900 $ via 2 900 000 unités, laissant un solde disponible de 589 000 $. Les produits serviront au fonds de roulement et au règlement des dettes commerciales. Les titres seront soumis à une période de détention de quatre mois et un jour à compter de l'émission.
Revive Therapeutics (OTCQB: RVVTF) hat eine Verlängerung seines Private-Placement-Angebots bekannt gegeben. Das Unternehmen beabsichtigt, bis zu $650.000 durch die Ausgabe von bis zu 30.952.381 Einheiten zu je $0,021 pro Einheit zu beschaffen. Jede Einheit umfasst eine Stammaktie und einen Warrant, der für 36 Monate zu $0,05 ausübbar ist.
Eine erste Tranche wurde bereits im August 2025 abgeschlossen, wobei $60.900 durch 2.900.000 Einheiten eingenommen wurden; verbleibend sind somit Einheiten im Wert von $589.000. Die Mittel sollen für das Working Capital und die Begleichung von Handelsverbindlichkeiten verwendet werden. Die Wertpapiere unterliegen ab Ausgabe einer Haltefrist von vier Monaten und einem Tag.
- First tranche already completed, raising $60,900
- Warrants provide potential additional funding at $0.05 per share
- Flexible closing structure allows for multiple tranches
- Significant dilution potential with up to 30.95M new shares
- Low unit price of $0.021 indicates potential financial stress
- Additional dilution possible through warrant exercise
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is extending is previously announced private placement offering of up to 30,952,381 units, at a price of
Each unit will consist of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to acquire one common share at an exercise price of
The gross proceeds from the private placement offering will be used for working capital and payment of certain trade payables. The proposed private placement may close in several tranches.
Closing of the private placement is subject to customary closing conditions and the Company intends to close as soon as practicable. All of the securities will be subject to a hold period of four months and one day from the date of issuance.
About Revive Therapeutics Ltd.
Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at www.sedarplus.ca.
FAQ
How much is Revive Therapeutics (RVVTF) looking to raise in their private placement?
What are the terms of RVVTF's private placement units?
How much has Revive Therapeutics already raised in the first tranche?
What will RVVTF use the private placement proceeds for?
How long is the hold period for the securities issued in RVVTF's private placement?
